Alamar Biosciences Inc ALMR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Alamar Biosciences to Participate in Upcoming Investor Conferences
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study
Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
UPDATE — Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
Trading Information
- Previous Close Price
- $26.91
- Day Range
- $26.35–28.15
- 52-Week Range
- $18.85–39.61
- Bid/Ask
- $25.16 / $34.00
- Shares Outstanding
- 69.48M
- Market Cap
- $1.95B
- Volume/Avg
- 536,162 / 593,784
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.alamarbio.com
Valuation
Metric | ALMR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.42 |
Price/Sales | 12.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ALMR |
|---|---|
Quick Ratio | 7.41 |
Current Ratio | 9.49 |
Interest Coverage | −71.05 |
Quick Ratio
ALMR
Profitability
Metric | ALMR |
|---|---|
Return on Assets (Normalized) | −17.33% |
Return on Equity (Normalized) | −67.92% |
Return on Invested Capital (Normalized) | −38.83% |
Return on Assets
ALMR
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|G^w>^m# | LOCK|KCqW | $190B | |||
| Medtronic PLC MDT | LOCK|F?p!jY | LOCK|@?VPP | $130B | |||
| Stryker Corp SYK | LOCK|NS$>%t^< | LOCK|ln> | $124B | |||
| Boston Scientific Corp BSX | LOCK|S!tWK# | LOCK|^LG% | $62B | |||
| Edwards Lifesciences Corp EW | LOCK|%qKRtht | LOCK|QGHBK | $59B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|r#tJRvM | LOCK|<G? | $37B | |||
| Koninklijke Philips NV ADR PHG | LOCK|?zH | LOCK|%Lf | $30B | |||
| DexCom Inc DXCM | LOCK|T^KMxv^ | LOCK|@!ZQ | $30B | |||
| Steris PLC STE | LOCK|WJQC%d | LOCK|%<&^ | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|Cg!F@Zbn | LOCK|<T? | $20B |
United States